Vzhľadom na to, že sa globálna ekonomika neustále vyvíja, je pochopenie najnovších finančných informácií dôležitejšie ako kedykoľvek predtým. Orientácia v zložitom svete financií môže byť ohromujúca, ale sledovanie významných trhových pohybov môže investorom a podnikom umožniť prijímať informované rozhodnutia. V nasledujúcom článku sa venujeme 5 najdôležitejším finančným trendom a udalostiam, ktoré majú potenciál ovplyvniť vývoj trhov v nadchádzajúcom týždni. Zahrnuli sme vás základnými správami, ktoré potrebujete vedieť, od výkonnosti akciových trhov až po pohyby vedúcich pracovníkov.

‍

Adobe Inc.  {{ m-tag option="price" ticker="ADBE" currency="USD" }}
‍

Overview:
‍
Adobe Inc. continues to be a dominant player in the creative software space, leading the industry with its Creative Cloud and Document Cloud platforms. With an expanding focus on AI-powered tools, such as Firefly, Adobe is positioned at the cutting edge of generative AI for design and digital content. However, the stock faces competitive challenges from other platforms, such as Canva and Figma.
‍

Key Metrics:
‍
For Q3 2024, Adobe is expected to report $5.37 billion in revenue, representing a 10% year-over-year growth. Its EPS is anticipated to be $4.53, reflecting 12% net income growth. Adobe’s P/E ratio stands at 50.59, with a market cap of $249.82 billion. The stock has a 52-week range of $433.98 to $638.25, and it recently closed at $567.93
‍​

Recent Updates:
‍
‍Adobe’s AI initiatives are a central driver of investor optimism, particularly its integration of Firefly into Photoshop and Illustrator. Stifel has raised Adobe's price target to $650, highlighting Adobe MAX, the company’s annual creativity conference, as a key catalyst for future growth.

Investors are also watching how Adobe capitalizes on the growing demand for AI-driven tools, with updates on AI monetization likely to impact the stock’s performance in the coming months​.

‍

Oracle Corp {{ m-tag option="price" ticker="ORCL" currency="USD" }}
‍

Overview:
‍
Oracle remains a key player in the cloud services and enterprise software space, with a growing focus on AI-driven cloud solutions. The company’s partnerships with Microsoft and OpenAI position it at the forefront of the next wave of AI workloads and cloud infrastructure. Oracle is also exploring opportunities to expand into new markets, including healthcare, through its acquisition of Cerner​.
‍
Key Metrics:
‍
Oracle is set to report its Q1 fiscal 2024 earnings, with analysts expecting $13.23 billion in revenue and an EPS of $1.33. The company’s cloud infrastructure revenue is projected to rise by 44% YoY to $2.18 billion, driven by increasing demand for AI workloads​.
Oracle’s P/E ratio stands at 38.25, with a market cap of $390.81 billion. The stock’s 52-week range is $99.26 to $146.59, with a recent close at $142.61.
‍
Recent Updates:
‍
Oracle is benefiting from its partnerships with Microsoft Azure and OpenAI, both of which contribute significantly to its cloud growth. The company has also been expanding its AI capabilities, particularly in healthcare cloud services​.

Investors are particularly interested in updates from Oracle’s CloudWorld conference, where the company is expected to announce strategic partnerships and further cloud innovations​.
‍

Regeneron Pharmaceuticals Inc {{ m-tag option="price" ticker="REGN" currency="USD" }}
‍

Overview:
‍
Regeneron Pharmaceuticals is a biotech leader, known for its blockbuster drugs Eylea (eye disorders) and Dupixent (immunology). The company is also making strides in oncology, with upcoming presentations at the WCLC and ESMO conferences. Regeneron is expanding its pipeline to include treatments for cardiovascular disease and obesity.
‍

‍Key Metrics:
‍
In Q2 2024, Regeneron reported $3.547 billion in revenue, marking a 12.32% YoY increase. Eylea and Dupixent continue to drive the company's growth, with Eylea sales rising 2% to over $1.5 billion. The company has a market cap of $124.73 billion, a P/E ratio of 29.96, and a 52-week range of $769.19 to $1,211.20​.

Recent Updates:
Regeneron is focusing on AI-driven drug discovery and antibody therapies. RBC Capital recently raised its price target to $1,282, citing the promising potential of Regeneron's Factor XI program, which could unlock a $3 billion market​ Hedge funds remain optimistic about the company's future, ranking it as a top biotech stock.
‍

‍

Delta Air Lines, Inc. {{ m-tag option="price" ticker="DAL" currency="USD" }}
‍

Overview:

‍Delta Air Lines is benefiting from the recovery in air travel demand, though rising fuel costs and inflation remain significant challenges. The airline reported strong passenger numbers in both domestic and international markets, despite facing cost pressures​.
‍

Key Metrics:

‍For Q2 2024, Delta posted $15.45 billion in adjusted revenue, a 5% YoY increase. However, a 12% rise in fuel costs led to a contraction in operating margin, from 17.1% to 14.7%​.

The stock is currently trading around $42.03, with a P/E ratio of 6.05 and a market cap of $27.13 billion. Delta’s 52-week range is $30.60 to $53.86.​
‍

Recent Updates:

‍Despite headwinds from fuel prices, Delta has reduced its total debt from $34.7 billion in 2021 to $24.8 billion in 2024. Analysts maintain a Buy rating, projecting the stock to reach $60.70​.

Delta is also navigating higher operational costs, but its long-term outlook remains positive as demand for air travel continues to recover.
‍

Qualcomm Inc {{ m-tag option="price" ticker="QCOM" currency="USD" }}
‍

Overview:

‍Qualcomm is a global leader in semiconductor technology, known for its dominance in mobile chipsets. However, the company has been expanding its business into automotive and IoT markets to reduce its dependence on the cyclical smartphone industry. Qualcomm is also reportedly exploring the acquisition of parts of Intel's PC chip design business​.
‍

Key Metrics:

‍Qualcomm generated $35.82 billion in revenue last year, with a market cap of $180.47 billion. The stock has a P/E ratio of 21.00 and a 52-week range of $104.33 to $230.63. Recently, Qualcomm closed at $158.19, with strong investor interest in its automotive and IoT growth potential​.
‍

Recent Updates:

‍Qualcomm's interest in acquiring Intel's PC chip design business is part of its broader strategy to expand beyond mobile chips. The company is also seeing growth in its automotive segment, with a design win pipeline of $45 billion, positioning it to generate $4 billion in auto-related revenue by 2026​.

Analysts view this diversification as a key growth driver, despite cyclical challenges in the smartphone industry​.
‍

Záver
‍

The coming week offers a range of opportunities across multiple sectors, from the potential growth in AI-driven services at Adobe and Oracle to the expansion of pharmaceutical pipelines at Regeneron and Qualcomm’s diversification into automotive and PC chip design. While challenges like inflation, fuel costs, and market competition persist, these companies offer strong growth potential for investors.
‍

Investor Guidance:
‍
As the market continues to evolve, investors should remain focused on key earnings reports and industry shifts. Keeping an eye on developments in AI, healthcare, and cloud computing will help in navigating both opportunities and risks in the coming week.

‍
Informácie na mexem.com slúžia len na všeobecné informačné účely. Nemali by sa považovať za investičné poradenstvo. Investovanie do akcií je spojené s rizikom. Minulá výkonnosť akcie nie je spoľahlivým ukazovateľom jej budúcej výkonnosti. Pred prijatím akéhokoľvek investičného rozhodnutia sa vždy poraďte s finančným poradcom alebo dôveryhodnými zdrojmi.
‍
‍